Dr. Marla Klein is recognized as a thought leader in aesthetic medicine and has been selected to be one of the first 50 physicians in the USA to work with the new micro-coring technology, Ellacor. It is a first of its kind scar-free skin reduction medical procedure. Click here to learn more. Ellacor is already FDA-approved for the lower face. There should be more areas to come as we gain more data about the procedure process.
Dr. Marla M. Klein MD is Oregon's pioneer of medical cosmetics. She started injecting Botox® in 1997. She is an Allergan Premier Partner and she has been injecting and teaching about Botox® and Juvederm® HA fillers since 2002. She is one of the most experienced injectors in the USA and has been seeing dermatology patients daily full-time since 1994.
Dr. Klein is recognized as a thought leader in aesthetic medicine and she was one of the first people chosen to be trained in the USA in the use of Sculptra®. Then she became the single Pacific Northwest Trainer to train other physicians from 2004-2014. Now she focuses on her private practice patients and the training and supervision of her own staff.
1987 – Two Canadian married doctors – Drs Jean and Alastair Carruthers, realized those getting injections for blepharospasms were also losing the lines near their eyes. They started to look into the anti-aging benefits of the product. Dr. Jean Carruthers is an ophthalmologist and related this finding to her husband, a dermatologist, Dr. Alastair Carruthers.
1988 – Pharmaceutical giant Allergan acquired the rights to Oculinum as it was then known.
1989 – Allergan renames the product ‘Botox®’ and it gets approved by the FDA a year later to treat crossed eyes and excessive blinking aka blepharospasm.
1992 – Drs Carruthers presented their findings of the wrinkle relaxing benefits of Botox®, but didn’t patent their idea due to poor legal advice. Allergan did however, and subsequently launched Botox®.
1996 – Dr. Marla Klein MD was trained to use Botox®. She and other doctors noticed that patients treated for forehead lines also sweated less, and that patients were reporting fewer headaches.
2002 – FDA approved Botox® for cosmetic use to minimize the appearance of wrinkles, primarily for the vertical lines between the eyebrows (glabella). Note that prior to this, Botox® had been used off-label to relax wrinkles.
2004 – FDA approves Botox® for excessive underarm sweating, known medically as axillary hyperhidrosis.
2005 – Dr. Jerome Lentini of Salem Oregon has a class action lawsuit filed against him for using bogus “botox”. He injected hundreds of cosmetic patients in Tigard and Salem Oregon with a non-FDA-approved botulism product that was linked to the near deaths of four Florida residents. He and his nurse served jail time.
2010 – FDA approves Botox® to treat chronic migraines.
2002 –2012 Allergan promised only to sell Cosmetic Botox® to their “core group” of physicians – dermatologists, plastic surgeons, and ophthalmologists. Dr. Klein was selected and participated in their National Educational Faculty. Allergan gained insight from their NEF by having them gather in meetings and share their observations and ideas with each other and Allergan staff. Dr. Klein stopped participating in NEF when she was asked to train med spa nurses, because she believes that owners of med spas should learn how and teach their nurses themselves.